The Curis Lifesciences IPO opens on November 7, 2025, and will close on November 11, 2025. The Curis Lifesciences IPO is a book-built issue. The company will raise approximately ₹27.52 crore through the IPO, consisting of fresh shares worth ₹27.52 crore and equity shares with a face value of ₹10.
The price band for the Curis Lifesciences IPO is ₹120 to ₹128 per share. The retail share is 35%, QIBs 50%, and HNIs 15%. The Curis Lifesciences IPO will be listed on the NSE on November 14, 2025. The allotment for the Curis Lifesciences IPO will take place on November 12, 2025.
The company reported revenue of ₹49.65 crore in 2025, compared to ₹35.87 crore in 2024. The company reported a profit of ₹6.11 crore in 2025, compared to ₹4.87 crore in 2024. Based on the financials, IPO investors should invest in IPO GMP for the long term.
Curis Lifesciences IPO Details
| IPO Open Date | November 7, 2025 |
| IPO Close Date | November 11, 2025 |
| Face Value | ₹10 Per Equity Share |
| IPO Price Band | ₹120 to ₹128 Per Share |
| Issue Size | Approx ₹27.52 Crores |
| Fresh Issue | Approx ₹27.52 Crores |
| Issue Type | Book Built Issue |
| IPO Listing | NSE SME |
| DRHP Draft Prospectus |  |
| RHP Draft Prospectus | |
Curis Lifesciences IPO Review & Key Points
- Review:
Curis Lifesciences IPO Market Lot
The Curis Lifesciences IPO minimum market lot is 2,000 shares with ₹2,56,000 application amount.
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 2 | 2,000 | ₹2,56,000 |
| Retail Maximum | 2 | 2,000 | ₹2,56,000 |
| S-HNI Minimum | 3 | 3,000 | ₹3,84,000 |
| S-HNI Maximum | 7 | 7,000 | ₹8,96,000 |
| B-HNI Minimum | 8 | 8,000 | ₹10,24,000 |
IPO Reservation
| Investor Category | Share Offered | -% Shares |
| Anchor Investor | 6,10,000 Shares | 28.37% |
| QIB (Ex. Anchor) | 4,08,000 Shares | 18.98% |
| NII Shares Offered | 3,08,000 Shares | 14.33% |
| Retail Shares Offered | 7,16,000 Shares | 33.30% |
Curis Lifesciences IPO Anchor Investors
| Anchor Bidding Date | November 6, 2025 |
| Anchor Investors List | . |
| Shares Offered | 6,10,000 Shares |
| Anchor Size | 7.81 Cr. |
| lock-in period end date 50% shares (30 Days) | December 12, 2025 |
| lock-in period end date 50% shares (90 Days) | February 10, 2026 |
Curis Lifesciences IPO Dates
The Curis Lifesciences IPO date is November 7 and the close date is November 11. The Curis Lifesciences IPO allotment will be finalized on November 12 and the IPO listing on November 14.
| IPO Open Date: | November 7, 2025 |
| IPO Close Date: | November 11, 2025 |
| Basis of Allotment: | November 12, 2025 |
| Refunds: | November 13, 2025 |
| Credit to Demat Account: | November 13, 2025 |
| IPO Listing Date: | November 14, 2025 |
| IPO Bidding Cut-off Time: | November 11, 2025 – 5 PM |
Promoters and Holding Pattern
The promoters of the company are Mr. Dharmesh Dashrathbhai Patel, Mr. Siddhant Jayantibhai Pawasia, Mr. Piyush Gordhanbhai Antala and Mr. Jaimik Mansukhbhai Patel..
| Particular | Shares | % Share |
| Promoter Holding Pre Issue | 59,34,434 | 92.68% |
| Promoter Holding Post Issue | 80,84,434 | 68.03% |
Objects of the Issue & Utilisation of proceeds
| Purpose | Crores |
| Capital Expenditure towards Upgradation/Improvement of the existing Manufacturing Facilities | ₹2.44 |
| Capital Expenditure towards Construction of a Storage Facility | ₹3.62 |
| Pre-payment/Repayment of outstanding Secured Loans | ₹1.86 |
| Product Registrations in other countries | ₹2.69 |
| Funding our Working Capital Requirements | ₹11.25 |
| General Corporate Purposes |
About Curis Lifesciences IPO
Established in 2010, Curis Lifesciences Limited is a leading pharmaceutical company that manufactures a wide range of pharmaceutical products, including tablets, capsules, external preparations, oral liquids, and sterile ophthalmic ointments. The company sources finished products from manufacturers and distributes them to wholesalers and other customers across the country. As of July 31, 2025, the company had a total of 95 permanent employees.
Curis Lifesciences manufactures medicines in India and abroad under contract or license agreements, as well as for its own brands. In addition to its two own-brand customers in Yemen and Kenya, the company contracts with over 100 corporate customers. Additionally, the company has a state-of-the-art factory in Sanand, Gujarat, where it follows strict quality control checks to ensure the safety and proper functioning of each of its products.
Curis Lifesciences IPO Company Financial Report
Amount ₹ in Crores
| Period Ended | Revenue | Expense | PAT | Assets |
| 2023 | ₹36.42 | ₹34.23 | ₹1.88 | ₹29.75 |
| 2024 | ₹35.87 | ₹28.70 | ₹4.87 | ₹33.88 |
| 2025 | ₹49.65 | ₹41.38 | ₹6.11 | ₹42.53 |
| July 2025 | ₹19.51 | ₹15.79 | ₹2.87 | ₹56.29 |
Curis Lifesciences IPO Valuation – FY2025
Check Curis Lifesciences IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| KPI | Values |
| ROE: | 55.25% |
| ROCE: | 27.83% |
| EBITDA Margin: | 19.41% |
| PAT Margin: | 12.43% |
| Debt to equity ratio: | 0.96 |
| Earning Per Share (EPS): | ₹10.29 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 37.62% |
| Net Asset Value (NAV): | ₹27.34 |
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Sotac Pharmaceuticals Limited | 4.32 | 18.30 | 9.00% | 47.99 | 64.76 Cr. |
| Lincoln Pharmaceuticals Limited | 41.11 | 12.21 | 12.27% | 335.34 | 645.71 Cr. |
About Curis Lifesciences Ltd.
Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.
The company manufactures pharmaceutical products globally and domestically on a loan license or contract basis, as well as for its own brand marketing.
The company serves over 100 corporate clients on loan licenses or contract manufacturing and 2 clients for its own brand marketing in Yemen and Kenya.
Products:
- General pharmaceutical tablets and capsules
- Oral liquids
- External preparations
- Sterile ophthalmic ointments
The company operates a state-of-the-art manufacturing facility in Sanand, Gujarat, adhering to stringent quality control measures to ensure product safety and efficacy.
As of July 31, 2025, the company has 95 permanent employees.
Competitive Strengths:
- Experienced Promoters and Management Team
- Wide range of Products
- Strategic Location of Manufacturing Facility
- Scalable Business Model
- Quality assurance